Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-12-02
2002-04-09
Eyler, Yvonne (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S325000, C536S023500
Reexamination Certificate
active
06368826
ABSTRACT:
BACKGROUND OF THE INVENTION
The IGF-1 receptor signaling system plays an important role in tumor proliferation and survival and is implicated in inhibition of tumor apoptosis. In addition and independent of its mitogenic properties, IGF-1R activation can protect against or at least retard programmed cell death in vitro and in vivo (Harrington et al.,
EMBO J.
13 (1994) 3286-3295; Sell et al.,
Cancer Res.
55 (1995) 303-305; Singleton et al.,
Cancer Res.
56 (1996) 4522-4529). A decrease in the level of IGF-1R below wild type levels was also shown to cause massive apoptosis of tumor cells in vivo (Resnicoff et al.,
Cancer Res.
55 (1995) 2463-2469; Resnicoff et al.,
Cancer Res.
55 (1995) 3739-3741). Overexpression of either ligand (IGF) and/or the receptor is a feature of various tumor cell lines and can lead to tumor formation in animal models. Overexpression of human IGF-1R resulted in ligand-dependent anchorage-independent growth of NIH 3T3 or Rat-1 fibroblasts and inoculation of these cells caused a rapid tumor formation in nude mice (Kaleko et al.,
Mol. Cell. Biol.
10 (1990) 464-473; Prager et al.,
Proc. Natl. Acad. Sci.
USA 91 (1994) 2181-2185). Transgenic mice overexpressing IGF-II specifically in the mammary gland develop mammary adenocarcinoma (Bates et al.,
Br. J. Cancer
72 (1995) 1189-1193) and transgenic mice overexpressing IGF-II under the control of a more general promoter develop an elevated number and wide spectrum of tumor types (Rogler et al.,
J. Biol. Chem.
269 (1994) 13779-13784). One example among many for human tumors overexpressing IGF-I or IGF-II at very high frequency (>80%) are Small Cell Lung Carcinomas (Quinn et al.,
J. Biol. Chem.
271 (1996) 11477-11483). Signaling by the IGF system seems to be also required for the transforming activity of certain oncogenes. Fetal fibroblasts with a disruption of the IGF-1R gene cannot be transformed by the SV40 T antigen, activated Ha-ras, or a combination of both (Sell et al.,
Proc. Natl. Acad. Sci.
USA 90 (1993) 11217-11221; Sell et al.,
Mol. Cell. Biol.
14 (1994) 3604-3612), and the E5 protein of the bovine papilloma virus is also no longer transforming (Morrione et al.,
J. Virol.
69 (1995) 5300-5303). Interference with the IGF/IGF-1R system was also shown to reverse the transformed phenotype and to inhibit tumor growth (Trojan et al.,
Science
259 (1993) 94-97; Kalebic et al.,
Cancer Res.
54 (1994) 5531-5534; Prager et al., Proc. Natl. Acad, Sci. USA 91 (1994) 2181-2185; Resnicoff et al.,
Cancer Res.
54 (1994) 2218-2222; Resnicoff et al.,
Cancer Res.
54 (1994) 4848-4850; Resnicoff et al.,
Cancer Res.
55 (1995) 2463-2469. For example, mice injected with rat prostate adenocarcinoma cells (PA-III) transfected with IGF-1R antisense cDNA (729 bp) develop tumors 90% smaller than controls or remained tumor-free after 60 days of observation (Burfeind et al.,
Proc. Natl. Acad. Sci.
USA 93 (1996) 7263-7268). IGF-1R mediated protection against apoptosis is independent of de-novo gene expression and protein synthesis. Thus, IGF-1 likely exerts its anti-apoptotic function via the activation of preformed cytosolic mediators.
Some signaling substrates which bind to the IGF-1R (e.g. IRS-1, SHC, p85 P13 kinase etc., for details see below) have been described. However, none of these transducers is unique to the IGF-1R and thus could be exclusively responsible for the unique biological features of the IGF-1R compared to other receptor tyrosine kinase including the insulin receptor. This indicates that specific targets of the IGF-1R (or at least the IGF-receptor subfamily) might exist which trigger survival and counteract apoptosis and thus are prime pharmaceutical targets for anti-cancer therapy.
By using the yeast two-hybrid system it was shown that p85, the regulatory domain of phosphatidyl inositol 3 kinase (P13K), interacts with the IGF-1R (Lamothe, B., et al.,
FEBS Lett.
373 (1995) 51-55; Tartare-Decker, S., et al.,
Endocrinology
137 (1996) 1019-1024). However binding of p85 to many other receptor tyrosine kinases of virtually all families is also seen. Another binding partner of the IGF-1R defined by two-hybrid screening is SHC which binds also to other tyrosine kinases such as trk, met, EGF-R and the insulin receptor (Tartare-Deckert, S., et al.,
J. Biol. Chem.
270 (1995) 23456-23460). The insulin receptor substrate 1 (IRS-1) and insulin receptor substrate 2 (IRS-2) were also found to both interact with the IGF-1R as well as the insulin receptor (Tartare-Deckert, S., et al.,
J. Biol. Chem.
270 (1995) 23456-23460; He, W., et al.,
J. Biol. Chem.
271 (1996) 11641-11645; Dey, R. B., et al.,
Mol. Endocrinol.
10 (1996) 631-641). Grb 10 which interacts with the IGF-1R also shares many tyrosine kinases as binding partners, e.g. met, insulin receptor, kit and abl (Dey, R. B., et al., Mol. Endocrinol. 10 (1996) 631-641; Morrione, A., et al.,
Cancer Res.
56 (1996) 3165-3167). The phosphatase PTP1D (syp) shows also a very promiscuous binding capacity, i.e. binds to IGF-1R, insulin receptor, met and others (Rocchi, S., et al.,
Endocrinology
137 (1996) 4944-4952). More recently, mSH2-B and vav were described as binders of the IGF-1R, but interaction is also seen with other tyrosine kinases, e.g. mSH2-B also bind to ret and the insulin receptor (Wang, J., and Riedel, H.,
J. Biol. Chem.
273 (1998) 3136-3139). Taken together, the so far described IGF-1R binding proteins represent relatively unspecific targets for therapeutic approaches, or are in the case of the insulin receptor substrates (IRS-1, IRS-2) indispensable for insulin-driven activities.
SUMMARY OF THE INVENTION
The present invention relates to IGF-1 receptor interacting proteins (IIPs); nucleic acids coding therefor; and their use for diagnostics and therapeutics, especially in the field of cancer. In particular, the invention relates to the identification of said genes in mammalian cells, especially in malignant tumor cells; to gene therapy methods for inhibiting the interaction between IGF-1 receptor and IIPs; methods of screening for potential cancer therapy agents; and cell lines and animal models useful in screening for and evaluating potentially useful pharmaceutical agents that inhibit the interaction between IIPs; and IGF-1 receptor.
The present invention relates in particular to the cloning and characterization of the gene IIP-10 and the gene products thereof. Said gene products (polypeptides, mRNA) are especially characterized as having the ability to modulate the IGF-1 receptor signaling pathway. The function of the gene products according to the invention is therefore to modulate signal transduction of the IGF-1 receptor. Forced activation of IIPs therefore correlates with increased tumor cell proliferation, survival and escape of apoptosis.
It is an object of the invention to provide novel genes encoding binding proteins of IGF-1R as well as the corresponding polypeptides which modulate, preferably activate the IGF-1 receptor signaling pathway. It is envisioned that this invention provides a basis for new cancer therapies based on the modulation, preferably inhibition, of the interaction between IGF-1 R and IIPs.
REFERENCES:
patent: 2915082 (1959-12-01), Shaw
patent: 063 879 (1982-11-01), None
patent: 128 018 (1984-12-01), None
patent: 173 251 (1986-03-01), None
patent: 200 362 (1986-12-01), None
patent: 89/06698 (1989-07-01), None
patent: 95/14772 (1995-06-01), None
patent: 97/27296 (1997-07-01), None
Stratagene 1993 Product Catalog, p. 43.*
NCI-CGAP, GenBank Accession No. AA515857, Nov. 13, 1997.*
Wang and Strittmatter, GenBank Accession No. AF061623, Nov. 10, 1998.*
De Vries et al., GenBank Accession No. AF089816, Oct. 24, 1998.*
De Vries et al., GenBank Accession No. AFO89817, Oct. 24, 1998.*
Lin et al., J. Exp. Clin. Cancer Res., vol. 15, pp. 319-326 (1996).
van der Laan et al., Thyroid, vol. 5, No. 1, pp. 67-73 (1995).
Rousset et al.,Oncogene, vol. 16, pp. 643-654 (1998).
De Vries et al.,Proc. Natl. Acad. Sci. USA, vol. 95, pp. 12340-12345 (1998).
No. XP-002102461, Database EMBL ID AF 032120, Bunn et a
Ligensa Tanja
Schumacher Ralf
Weidner Michael
Andres Janet L.
Dubberley F. Aaron
Eyler Yvonne
Hoffmann-La Roche Inc.
Johnston George W.
LandOfFree
IGF-1 receptor interacting proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IGF-1 receptor interacting proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF-1 receptor interacting proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2896912